

David J Moliterno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5601634/publications.pdf>

Version: 2024-02-01

22
papers

5,188
citations

567281

15
h-index

794594

19
g-index

47
all docs

47
docs citations

47
times ranked

6865
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Evolving our learning and application of knowledge to practiceâ€”The ongoing challenges of time and cost in interventional cardiology. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 17-18. | 1.7 | 0 |
| 2 | Acute ischemic stroke and the acute need for expansion of stroke teams and their membership. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 475-476. | 1.7 | 0 |
| 3 | Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021, 42, 4683-4693. | 2.2 | 18 |
| 4 | Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2021, 6, 1032. | 6.1 | 27 |
| 5 | Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021, 42, 4624-4634. | 2.2 | 54 |
| 6 | Finding sideline benefits-Of pandemics and same-day-discharge following rotational atherectomy. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 689-690. | 1.7 | 1 |
| 7 | Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545. | 2.2 | 93 |
| 8 | Coronary interventions among patients with hepatic insufficiency: Encouragement to avoid a jaundiced view. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 811-812. | 1.7 | 0 |
| 9 | Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1704-1711. | 3.4 | 2 |
| 10 | Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042. | 27.0 | 683 |
| 11 | Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006144. | 3.9 | 24 |
| 12 | Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1638-1646. | 1.6 | 19 |
| 13 | Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>European Heart Journal</i> , 2017, 38, ehw525. | 2.2 | 164 |
| 14 | Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. <i>International Journal of Cardiology</i> , 2017, 243, 132-139. | 1.7 | 11 |
| 15 | White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, . | 3.9 | 32 |
| 16 | Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of) Tj ETQq0 0 0 rgBT /Overlock 10 2017, 120, 904-910. | 1.6 | 10 |
| 17 | Safety of an abbreviated duration of dual antiplatelet therapy (â‰¥6 months) following secondâ€“generation drugâ€“eluting stents for coronary artery disease: A systematic review and metaâ€“analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 722-732. | 1.7 | 17 |
| 18 | Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1349-1357. | 2.9 | 54 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. Journal of the American College of Cardiology, 2016, 67, 2224-2234. | 2.8 | 445 |
| 20 | Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722. | 13.7 | 537 |
| 21 | Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598. | 2.8 | 2,558 |
| 22 | Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents. Journal of the American College of Cardiology, 2007, 49, 734-739. | 2.8 | 432 |